人脐带间充质干细胞作为细胞载体治疗胶质瘤的研究现状及前景

发布时间：2018-06-01 23:24

本文选题：人脐带间充质干细胞 + 神经胶质瘤　；参考：《河北医科大学》2017年硕士论文

【摘要】：人脐带间充质干细胞(Hu MSCs)具有分化为各种品种细胞的多分化潜能,且无免疫排异反应,被认为是一种较理想的神经干细胞来源,同时也是基因治疗的理想细胞载体。脑胶质瘤因呈浸润性生长,与正常脑组织多无明显界限,手术难以彻底切除,成为肿瘤复发的主要来源。基因治疗已成为胶质瘤治疗的新手段,携带目的基因载体通过一定方式导入人脐带间充质干细胞以纠正基因的缺陷或者发挥其他作用。Hu MSCs势必成为一种神经干细胞的理想来源,在脑胶质瘤的基因治疗中发挥更大的作用。因此,本文就人脐带间充质干细胞作为细胞载体治疗胶质瘤的现状及前景作一综述。
[Abstract]:Human umbilical cord mesenchymal stem cells (HMSCs) have the potential to differentiate into various varieties of cells and have no immune rejection reaction. It is considered as an ideal source of neural stem cells and an ideal cell carrier for gene therapy. Glioma is the main source of tumor recurrence due to its infiltrating growth, which has no obvious boundary with normal brain tissue and is difficult to be completely resected. Gene therapy has become a new method of glioma therapy. Carrying the target gene vector into human umbilical cord mesenchymal stem cells in a certain way to correct gene defects or play other roles. Hu MSCs is bound to become an ideal source of neural stem cells. It plays a more important role in gene therapy of glioma. Therefore, the present situation and prospects of human umbilical cord mesenchymal stem cells as cell carriers in the treatment of gliomas are reviewed.
【学位授予单位】：河北医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R739.41

【参考文献】